Bridgewater Associates LP Has $260,000 Stock Holdings in Enovis Co. (NYSE:ENOV)

Bridgewater Associates LP trimmed its position in Enovis Co. (NYSE:ENOV - Free Report) by 66.4% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 5,915 shares of the company's stock after selling 11,673 shares during the quarter. Bridgewater Associates LP's holdings in Enovis were worth $260,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also modified their holdings of the company. Mariner LLC raised its stake in Enovis by 16.8% during the 4th quarter. Mariner LLC now owns 7,925 shares of the company's stock valued at $348,000 after purchasing an additional 1,142 shares during the last quarter. Sterling Capital Management LLC lifted its stake in Enovis by 56.2% during the fourth quarter. Sterling Capital Management LLC now owns 3,259 shares of the company's stock worth $143,000 after purchasing an additional 1,173 shares during the period. Kennedy Capital Management LLC lifted its stake in Enovis by 5.8% during the fourth quarter. Kennedy Capital Management LLC now owns 158,557 shares of the company's stock worth $6,957,000 after purchasing an additional 8,743 shares during the period. Treasurer of the State of North Carolina boosted its holdings in Enovis by 2.5% during the fourth quarter. Treasurer of the State of North Carolina now owns 24,347 shares of the company's stock valued at $1,068,000 after purchasing an additional 590 shares in the last quarter. Finally, Scotia Capital Inc. bought a new stake in shares of Enovis in the 4th quarter valued at approximately $598,000. 98.45% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Separately, Needham & Company LLC reaffirmed a "buy" rating and issued a $64.00 price target on shares of Enovis in a research note on Wednesday, April 9th.

Enovis Price Performance

Shares of NYSE ENOV traded down $0.11 during mid-day trading on Friday, hitting $35.01. 890,659 shares of the stock were exchanged, compared to its average volume of 750,101. The stock's fifty day simple moving average is $36.51 and its two-hundred day simple moving average is $41.95. Enovis Co. has a twelve month low of $29.32 and a twelve month high of $56.43. The company has a market cap of $2.00 billion, a P/E ratio of -15.99 and a beta of 1.86. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.12 and a current ratio of 2.27.

Enovis (NYSE:ENOV - Get Free Report) last posted its quarterly earnings data on Wednesday, February 26th. The company reported $0.98 earnings per share for the quarter, beating the consensus estimate of $0.92 by $0.06. Enovis had a negative net margin of 5.95% and a positive return on equity of 4.39%. The firm had revenue of $560.98 million during the quarter, compared to analysts' expectations of $555.14 million. As a group, analysts forecast that Enovis Co. will post 2.79 EPS for the current fiscal year.

About Enovis

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.